Navigation Links
Argos Therapeutics' Arcelis™ Immunotherapy for the Treatment of Renal Cell Carcinoma (RCC) in Combination With Sunitinib Demonstrates Strong Immunologic Response That Correlates to Improved Clinical Outcomes
Date:6/1/2011

DURHAM, N.C., June 1, 2011 /PRNewswire/ -- Argos Therapeutics announced today that its Arcelis™ immunotherapy for the treatment of renal cell carcinoma (RCC), AGS-003, in combination with sunitinib demonstrated a strong immunologic response that correlated to improved clinical outcomes. The Phase 2 combination study in newly diagnosed, metastatic RCC patients with unfavorable prognosis demonstrated decreases in T regulatory cells, along with a concurrent expansion of CD28+memory cytotoxic T lymphocytes (CTL). Results will be presented by Dr. Robert Figlin, director of the Division of Hematology/Oncology at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute, in a poster and a discussion session at 8 a.m. CDT, and noon CDT, respectively, Saturday, June 4, 2011, at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

The study is the first to demonstrate the combined immunologic and clinical effects of AGS-003, or any active immunotherapy, with sunitinib. Most patients experienced reversal of baseline tumor-induced immunosuppression and showed improved progression-free survival (PFS) compared to the expected PFS with sunitinib alone in an unfavorable risk, metastatic RCC patient population. Assessment of immunodynamicsusing multiparametric flow cytometry was performed on peripheral blood mononuclear cells isolated from blood draws collected prior to treatment and after treatment with AGS-003 during combination administration with sunitinib. Nine of 11 patients with PFS of >10 months demonstrated CTL population increases whereas two of four patients with PFS <10 months showed increases in this specific CTL population. Updates on the correlation between prolonged PFS and CTL expansion will be presented during ASCO.

"The study provides initial evidence that AGS-003
'/>"/>

SOURCE Argos Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Interleukin (IL)-12 Secretion Can Predict Potency of Argos Therapeutics Arcelis™ Dendritic Cell (DC) Immunotherapy and Can Be Used as Potency Marker in Phase 3 Clinical Trial
2. Argos Therapeutics to Present Potential of its Arcelis™ Immunotherapy as an Innovative, Effective Treatment for HIV at the APHA 138th Annual Meeting & Exposition
3. Argos Therapeutics to Present Overview of its Arcelis™ Dendritic Cell-based Immunotherapy, Participate in Panel Discussion at Inaugural Cancer Immunotherapy Conference
4. Argos Therapeutics to Present Recent Clinical Developments and Corporate Overview at 18th Annual BioPartnering Europe
5. Results From Argos Therapeutics Arcelis™ Immunotherapy Phase 2 Study for Treatment of Renal Cell Carcinoma (RCC) Accepted for Poster Presentation at Ninth International Kidney Cancer Symposium
6. Nektar Therapeutics President and CEO Howard W. Robin to Present at the Jefferies 2011 Global Healthcare Conference in New York
7. Reportlinker Adds Cancer Pain Therapeutics - Pipeline Assessment and Market Forecasts to 2017
8. Reportlinker Adds Myelodysplastic Syndrome Therapeutics - Pipeline Assessment and Market Forecasts to 2017
9. Cell Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Rule
10. Amicus Therapeutics to Present at Jefferies 2011 Global Healthcare Conference on Tuesday, June 7, 2011
11. Reportlinker Adds Risk Evaluation and Mitigation Strategy (REMS) - Opioids, Erythropoesis-Stimulating Agents and Cancer Therapeutics are the Most Important Classes That Require REMS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... DUBLIN , Aug. 4, 2015 /PRNewswire/ ... announced the addition of Jain PharmaBiotech,s new ... Markets, and Companies" to their offering. ... transdermal drug delivery - an approach used ... therapeutic use as an alternative to oral,intravascular, ...
(Date:8/4/2015)... Concord Medical Services Holdings Limited ("Concord Medical", or the "Company") ... operator of the largest network of radiotherapy and diagnostic imaging ... will release its financial results for the second quarter of ... Management will hold a conference call to discuss the ... 18, 2015 (8:00 p.m. in Beijing / ...
(Date:8/4/2015)... , August 4, 2015 ... with market overview, trends, DRO analysis, market segmentation, ... competitive scenario and top competitor profiles in: ... Testing Market Development and Demand Forecast to 2020  ... Explore full reports with detailed TOC ...
Breaking Medicine Technology:Transdermal Drug Delivery Report 2015-2024 - Technologies, Markets, and Companies Analysis 2Concord Medical to Report Second Quarter 2015 Financial Results on August 17, 2015 2Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 2Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 3Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 4Global Drug of Abuse (DOA) Testing Market (Size of $2.9 Billion in 2014) to Witness 5% CAGR During 2015 - 2020 5
... The American College of Medical Genetics (ACMG) ... decision to make Critical Congenital Cyanotic Heart Disease (CCCHD) ... Secretary,s Advisory Committee on Heritable Disorders in Newborns and ... MD, FACMG had made the recommendations to Secretary Kathleen ...
... 2011 Visionsense Corp announces an unique milestone this ... 500th neurosurgical procedure with the VSii system. ... Vice-Chairman, Dept of Neurosurgery at Emory University and Professor ... of a pituitary adenoma in the morning of September ...
Cached Medicine Technology:American College of Medical Genetics Applauds HHS Secretary's Decision to Expand Newborn Screening to Include Critical Congenital Heart Disease 2
(Date:8/4/2015)... , ... August 04, 2015 , ... ... which provides vascular, electrocardiogram (EKG), echocardiogram, and NCV testing, announced their collegiate ... successfully identifying previously undiagnosed cardiovascular abnormalities one program at a time. ...
(Date:8/4/2015)... ... August 04, 2015 , ... Angelina Jolie is in ... millions of women every year. Dr. Angela DeRosa, DO, MBA, CPE aka ... therapies, takes the scary unknown out of menopause. , Myth #1: Menopause only ...
(Date:8/4/2015)... Diego, CA (PRWEB) , ... August 04, 2015 ... ... the Rise of Local Food,” scheduled for Nov. 3 – 4, 2015, at ... grow food sustainably, create new businesses, improve food access, and manage resources efficiently ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... 24/7 ... County, Los Angeles, Riverside, and San Bernardino, today announced that the U.S. Department of ... indicate that 24/7 Care At Home’s agency is well on the path to meeting ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... label design, product packaging, and fulfillment services, joined over 200 other Long Island-based ... was held on Tuesday, July 28th at Jones Beach State Park in Wantagh, ...
Breaking Medicine News(10 mins):Health News:Colleges and High Schools Across the Country Are Joining the Wimbledon U Team Uncovering Unknown Cardiac Conditions and Promoting Heart Healthy Athletes 2Health News:Colleges and High Schools Across the Country Are Joining the Wimbledon U Team Uncovering Unknown Cardiac Conditions and Promoting Heart Healthy Athletes 3Health News:"Dr. Hot Flash" Debunks the Top 5 Menopause Myths 2Health News:"Dr. Hot Flash" Debunks the Top 5 Menopause Myths 3Health News:Diversity of Urban and Hydroponic Farms of the Future to Highlight Seedstock Annual Conference Field Trip 2Health News:Diversity of Urban and Hydroponic Farms of the Future to Highlight Seedstock Annual Conference Field Trip 3Health News:24/7 Care At Home Receives Two Stars from the VA 2Health News:24/7 Care At Home Receives Two Stars from the VA 3Health News:NutraScience Labs "Steps Up" to the 2015 Marcum Workplace Challenge 2
... President Obama and Secretary of State Clinton on today,s nomination ... the Global AIDS Coordinator (OGAC). AIDS Action is pleased ... led by such an accomplished HIV medical expert with extensive ... including the epidemic here in the United States. We ...
... 2009 (BRONX, NY) A laboratory study by researchers ... that an anti-cancer compound studied for treating blood cancers may ... The work is reported in the April 28th online edition ... neck cancer refers to tumors in the mouth, throat, or ...
... Findings from clinical studies used to gain Food and ... most patients with depression, according to a report led by ... in the May issue of the American Journal of ... people with depression qualify for these studies, and those who ...
... With growing concerns about the current spread of ... face masks protect against swine flu?"Tony Hanson, Managing Director ... an innovative, technologically advanced system of medical face masks ... this time it is believed that the current strain ...
... Inc. today announced that it named Dr. Robert Ruffolo, ... leader in pharmaceutical research to its Scientific Advisory Board. ... Development in 2008, and currently serves as a consultant ... and has been responsible for all pharmaceutical research and ...
... Embrace Use of Targeted Agents Despite Their High ... WALTHAM, Mass., April 28 Decision Resources, one ... focusing on pharmaceutical and healthcare issues, finds that ... Indian brand/generics (capecitabine) will dominate the Indian colorectal ...
Cached Medicine News:Health News:AIDS Action Applauds Selection of Dr. Eric Goosby as Global AIDS Coordinator 2Health News:Experimental drug shows promise against head and neck cancer 2Health News:Are we cherry picking participants for studies of antidepressants? 2Health News:Will Face Masks Protect Against Swine Flu? 2Health News:Gene Network Sciences Names Former Wyeth President of R&D Robert Ruffolo to SAB 2Health News:Gene Network Sciences Names Former Wyeth President of R&D Robert Ruffolo to SAB 3Health News:Sanofi-Aventis' and Roche/Chugai's Drugs Will Dominate the Indian Colorectal Cancer Drug Market Through 2013 2
... the only dura material versatile enough for ... closure, and in cases where biological fixation ... in cases requiring an immediate watertight seal ... biological fixation and sealing are key factors ...
The Bovie IDS Series are the latest electrosurgical generators with fully digital implementation....
Aaron 1250 is a multipurpose electrosurgical generator with monopolar and bi-polar functions....
Bipolar foot activated forceps....
Medicine Products: